A great deal of money will be necessary to fund: research, study, testing. It may be possible that B1 could evolve into a more efficient treatment.
Here is information that I have on file.
“As you all know we submitted to the Michael J Fox Foundation a project proposal for a clinical trial involving the High Dose Thiamine treatment. Although the pre-proposal was invited for further development (stage 1) unfortunately the proposal has been rejected by the reviewers at stage 2.
The reviewers expressed various concerns and a general skepticism about the impact that thiamine with the protocol developed by Dr. Costantini can actually have on PD. The three reviewers although contradicting each other on specific sections of the review, generally implied that the research is not groundbreaking and novel enough, not very trustworthy, same goes for our design (based on dose titration aka giving each patient its efficient dosage or else no improvements can be seen whereas they would have preferred a one size fits all type of dosage) and the lack of experience and reputation of us as Investigators. Reviewers also pointed out that our estimates concerning the recruitment of patients were far too optimistic (200 patients from two of the largest hospitals in Italy in 12 months), one highlighted that the budget we estimated for the clinical trial was too low to be true and in general said that our proposal is unrealistic and the expected results would not be very relevant to the PD community.
I am very sorry but this is their verdict and we can only accept it even though I personally feel this is a missed opportunity for many PD patients.” End Item